Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1196INDUSTRY 1019NIH 68NETWORK 17OTHER_GOV 16FED 5UNKNOWN 2INDIV 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Pemetrexed 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × pembrolizumab × Clear all
NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

ChineseAMS

Phase 2 Unknown
20 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02346955 2020-08-27

MK-6018-001

KitovPharma

Phase 1 Terminated
27 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡